Want to see TSE:EDT full AI Analyst Report?
EDT Stock Chart & Stats
C$1.33
C$0.02(1.48%)
At close: 4:00 PM EDT
C$1.33
C$0.02(1.48%)
Day’s Range― - ―
52-Week RangeC$1.13 - C$1.65
Previous CloseN/A
Volume5.21K
Average Volume (3M)50.43K
Market Cap
C$365.35M
Enterprise ValueC$411.25
Total Cash (Recent Filing)C$803.00K
Total Debt (Recent Filing)C$25.68M
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Nov 06, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend Yield47.06%
Share Statistics
EPS (TTM)-0.13
Shares Outstanding294,640,630
10 Day Avg. Volume27,849
30 Day Avg. Volume50,427
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)-5.93
Price to Sales (P/S)169.36
P/FCF Ratio-42.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)C$2.82M
Bulls Say, Bears Say
Bulls Say
Integrated Critical-Care PlatformPairing a targeted endotoxin-removal therapy with a diagnostic intended to identify suitable patients can support a differentiated clinical-care proposition. This integrated platform may improve treatment targeting and create a stronger commercialization opportunity than relying on an undifferentiated device alone.
FDA Regulatory ProgressFDA acceptance of the PMX submission is a meaningful de-risking milestone for a clinical-stage device company. Continued review progress can advance the product toward commercialization, potentially expanding future revenue opportunities and validating the regulatory pathway for the core therapy.
Clinical And Commercialization ProgressSupportive follow-up results strengthen the evidence base behind the company’s therapeutic approach, while commercialization planning indicates progress beyond development alone. Together, these developments may improve adoption prospects if regulatory review and financing support continued execution.
Bears Say
Severe UnprofitabilityThe company’s current revenue base is far too small to absorb its operating cost structure, producing exceptionally severe losses and negative gross profit. Unless margins improve materially with scale, ongoing unprofitability will continue consuming capital and delay a credible path to break-even.
Persistent Cash BurnSustained operating and free-cash-flow deficits indicate that the business cannot currently fund development and operations internally. Continued cash burn increases dependence on external financing, leaving execution vulnerable to funding availability and potentially constraining investment in commercialization.
Stressed Balance SheetNegative equity, materially higher debt, and a very thin asset base leave limited financial cushion against further losses. This weak balance-sheet position can restrict strategic flexibility, increase solvency pressure, and make future financing more important to sustaining the company’s operations.
Spectral Medical News
EDT FAQ
What was Spectral Medical’s price range in the past 12 months?
Spectral Medical lowest stock price was C$1.13 and its highest was C$1.65 in the past 12 months.
What is Spectral Medical’s market cap?
Spectral Medical’s market cap is C$365.35M.
When is Spectral Medical’s upcoming earnings report date?
Spectral Medical’s upcoming earnings report date is Nov 06, 2026 which is in 48 days.
How were Spectral Medical’s earnings last quarter?
Spectral Medical released its earnings results on Aug 07, 2026. The company reported C$0 earnings per share for the quarter, beating the consensus estimate of -C$0.01 by C$0.01.
Is Spectral Medical overvalued?
According to Wall Street analysts Spectral Medical’s price is currently Overvalued.
Does Spectral Medical pay dividends?
Spectral Medical pays a Notavailable dividend of C$0.12 which represents an annual dividend yield of 47.06%. See more information on Spectral Medical dividends here
What is Spectral Medical’s EPS estimate?
Spectral Medical’s EPS estimate is -0.01.
How many shares outstanding does Spectral Medical have?
Spectral Medical has 294,640,630 shares outstanding.
What happened to Spectral Medical’s price movement after its last earnings report?
Spectral Medical reported an EPS of C$0 in its last earnings report, beating expectations of -C$0.01. Following the earnings report the stock price went up 0.714%.
Which hedge fund is a major shareholder of Spectral Medical?
Currently, no hedge funds are holding shares in TSE:EDT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Spectral Medical
Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, Russia, and internationally. The company markets Endotoxin Activity Assay, a rapid in-vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B-Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops, manufactures, and markets monoclonal and polyclonal antibodies, recombinant cardiac proteins, antibodies, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.
Technical Analysis
Cipher Pharmaceuticals
―
BioMark Diagnostics
―
―
Profound Medical
―
Sona Nanotech Inc
―